Home
/
Conditions
/ Erectile Dysfunction
Men's Health
Schedule a Consultation
Erectile Dysfunction
Erectile dysfunction is not a stand-alone diagnosis. It is the earliest clinical manifestation of vascular, hormonal, metabolic, and neurological dysfunction that predicts cardiovascular events by 3 to 5 years. The penile arteries are among the smallest in the body and are affected first when endothelial function, nitric oxide production, testosterone, and insulin sensitivity decline. At The Lamkin Clinic, erectile dysfunction is evaluated as a systemic vascular and metabolic condition with identifiable root causes, not simply treated with a PDE5 inhibitor prescription.
Men's HealthVascular Early WarningHormonal and Metabolic
3 to 5 YearsED precedes cardiovascular events as the earliest vascular warning sign
Multi-Systemvascular, hormonal, metabolic, and neurological mechanisms converge
Treatablewhen the specific biological drivers are identified and corrected
← Back to Conditions
Condition: Erectile Dysfunction | Category: Men's Health | Reviewed by: Brian Lamkin, DO
What Is Erectile Dysfunction?
Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. While commonly treated as an isolated urological complaint with a PDE5 inhibitor prescription, ED is in fact a systemic vascular and metabolic condition. The penile arteries (1 to 2mm diameter) are among the smallest in the body and are affected by endothelial dysfunction before larger coronary arteries (3 to 4mm) become clinically impaired. This makes ED the earliest detectable sign of the same vascular disease process that produces heart attacks and strokes.
Erection requires the coordinated function of four systems: vascular (endothelial nitric oxide production to relax penile smooth muscle and increase blood flow), hormonal (testosterone for nitric oxide synthase expression and libido), neurological (parasympathetic signaling to initiate the process), and metabolic (insulin sensitivity supporting endothelial function). Dysfunction in any one of these systems produces ED. In most men over 40, multiple mechanisms are active simultaneously.
Critical principle: A man presenting with erectile dysfunction should receive a comprehensive cardiovascular risk evaluation, not just a Viagra prescription. ED is a 3 to 5 year warning window during which the vascular disease process that will produce a cardiovascular event is identifiable and modifiable. Treating ED with a PDE5 inhibitor alone addresses the symptom while the disease process that produced it continues to progress.
Why Erectile Dysfunction Matters
Cardiovascular Risk Indicator
- ED precedes cardiovascular events by 3 to 5 years: the same endothelial dysfunction producing ED is simultaneously affecting coronary, cerebral, and peripheral arteries
- ED is an independent cardiovascular risk factor equivalent in predictive value to smoking, hypertension, and diabetes
- Men with ED have double the cardiovascular event risk compared to age-matched men without ED, even after adjusting for traditional risk factors
- ED severity correlates with cardiovascular risk severity: complete ED has higher predictive value than intermittent difficulty
Why Standard ED Treatment Is Incomplete
- PDE5 inhibitors treat the symptom but not the cause: they enhance nitric oxide signaling temporarily but do not address the endothelial dysfunction, testosterone deficiency, or insulin resistance producing the problem
- No cardiovascular evaluation is performed: standard ED treatment does not include fasting insulin, hs-CRP, advanced lipids, or endothelial function assessment
- Hormonal evaluation is often incomplete: total testosterone alone misses free testosterone, SHBG, estradiol, and the metabolic context that determines hormonal adequacy
- The disease process continues: the patient gets erections with medication while the vascular disease producing the ED progresses toward a cardiovascular event
Common Symptoms
Erectile Function
- Difficulty achieving erection
- Difficulty maintaining erection during intercourse
- Reduced rigidity of erection
- Loss of spontaneous morning erections
Hormonal Indicators
- Decreased libido
- Fatigue and reduced energy
- Loss of muscle mass
- Depressed mood or irritability
Metabolic and Vascular
- Visceral weight gain
- Elevated blood pressure
- Dyslipidemia (high triglycerides, low HDL)
- Post-meal fatigue (insulin resistance indicator)
Root Causes: A Functional Medicine Perspective
Erectile dysfunction has identifiable biological mechanisms that functional medicine evaluates and treats at the source rather than bypassing with medication.
Endothelial Dysfunction and Nitric Oxide Deficiency
Endothelial dysfunction is the most common vascular cause of ED. The endothelium produces nitric oxide (NO) through endothelial nitric oxide synthase (eNOS). NO relaxes penile smooth muscle, increases blood flow, and enables erection. Insulin resistance, chronic inflammation, oxidative stress, and hypertension all impair eNOS function and reduce NO availability. hs-CRP elevation identifies the inflammatory contribution to endothelial impairment.
Testosterone Deficiency and Hormonal Imbalance
Testosterone is required for nitric oxide synthase expression in penile tissue, for libido, and for the neurological sensitivity that initiates arousal. Total testosterone alone is insufficient for evaluation: free testosterone (the biologically active fraction), SHBG (which binds and inactivates testosterone), and estradiol (elevated by aromatase in visceral fat, which suppresses testosterone signaling) must all be assessed. Andropause produces progressive free testosterone decline beginning in the late 30s that compounds the vascular mechanisms.
Insulin Resistance and Metabolic Dysfunction
Insulin resistance is present in a large proportion of men with ED. It directly impairs eNOS, promotes vascular inflammation, and produces visceral adiposity that increases aromatase conversion of testosterone to estradiol. Fasting insulin and HOMA-IR identify the metabolic contribution. Many men with ED and "normal testosterone" have insulin-driven estradiol elevation that is suppressing their effective testosterone signaling.
Conventional vs Functional Medicine Approach
| Domain | Conventional Medicine | Functional Medicine |
|---|---|---|
| Assessment | Brief history, total testosterone; PDE5 inhibitor prescription | Comprehensive: free testosterone, SHBG, estradiol, fasting insulin, hs-CRP, advanced lipids, thyroid panel, cardiovascular risk assessment |
| Treatment | PDE5 inhibitor (sildenafil, tadalafil) | Root-cause specific: testosterone optimization, insulin sensitization, endothelial restoration, aromatase management, with PDE5 inhibitor as bridge |
| Cardiovascular | Not routinely assessed | ED treated as cardiovascular early warning with comprehensive vascular risk evaluation |
| Outcome | Medication-dependent erections; vascular disease continues | Restored function through biological correction; cardiovascular risk simultaneously reduced |
Key Labs to Evaluate
Free TestosteroneBiologically active testosterone fraction. More clinically meaningful than total testosterone alone.
→Total TestosteroneBaseline testosterone assessment. Must be interpreted with free T and SHBG.
→EstradiolElevated estradiol from aromatase suppresses testosterone signaling and contributes to ED.
→Fasting InsulinThe metabolic driver of endothelial dysfunction and aromatase-mediated estradiol elevation.
→hs-CRPVascular inflammation marker. Elevated hs-CRP identifies inflammatory endothelial impairment.
→How to Interpret These Labs Together
Free testosterone low with elevated estradiol and elevated fasting insulin identifies the metabolic-hormonal ED pattern: insulin resistance is producing visceral adiposity, visceral fat is producing aromatase, aromatase is converting testosterone to estradiol, and the resulting hormonal imbalance is compounded by insulin-mediated endothelial dysfunction. Three mechanisms from one metabolic root cause. Insulin sensitization plus aromatase management resolves the hormonal and vascular impairment simultaneously.
Normal testosterone with elevated hs-CRP and elevated fasting insulin identifies vascular ED from endothelial dysfunction without a primary hormonal driver. The ED is driven by impaired nitric oxide production from inflammation and insulin resistance. Treatment: insulin sensitization, anti-inflammatory protocols, L-citrulline for nitric oxide substrate support. PDE5 inhibitor as bridge while vascular function is restored.
Low total and free testosterone with normal insulin and normal hs-CRP identifies primary hypogonadism as the driver. This is the patient who benefits most directly from bioidentical testosterone replacement. LH and FSH help differentiate primary (testicular) from secondary (pituitary) causes.
Common Patterns Seen in Patients
- The 45-year-old on sildenafil who has never had labs drawn: Using PDE5 inhibitors for 3 years without any investigation. Free testosterone in the lower 10th percentile, fasting insulin 18, estradiol elevated, hs-CRP 2.8, triglyceride/HDL ratio 5.2. Four independent mechanisms producing ED, all progressing toward a cardiovascular event, all invisible because labs were never drawn. Comprehensive intervention: testosterone optimization, insulin sensitization, estradiol management, cardiovascular risk reduction. PDE5 inhibitor tapered and discontinued at 4 months as endogenous function restored.
- The 52-year-old told "this is normal at your age": Progressive ED over 2 years attributed to aging. Total testosterone 380 (reported as "normal"). Free testosterone calculated at 5.2 ng/dL (functionally low). SHBG elevated at 62 (binding and inactivating available testosterone). Estradiol 42 (suppressing HPG axis). Fasting insulin 14. The "normal" total testosterone was masking significantly impaired free testosterone availability. Testosterone optimization with SHBG and aromatase management restored function.
- The diabetic with ED and no cardiovascular evaluation: Type 2 diabetic on metformin and a PDE5 inhibitor. Never had hs-CRP, advanced lipids, or endothelial function assessed. The ED was being treated as a side effect of diabetes rather than as a cardiovascular warning. hs-CRP 4.1, triglyceride/HDL ratio 6.8, fasting insulin 22 despite metformin. Aggressive metabolic optimization, anti-inflammatory protocols, and cardiovascular risk reduction alongside testosterone evaluation.
Treatment and Optimization Strategy
Multi-Mechanism ED Restoration
Vascular and Metabolic
- Insulin sensitization through low-glycemic nutrition and time-restricted eating to restore endothelial function at the metabolic level
- L-citrulline (3 to 6g daily) for nitric oxide substrate support and endothelial function enhancement
- Anti-inflammatory protocols (omega-3 3 to 4g EPA+DHA, curcumin) to reduce vascular inflammation
- Resistance training for testosterone stimulation, insulin sensitization, and cardiovascular conditioning
- PDE5 inhibitor (tadalafil 5mg daily or sildenafil as needed) as bridge therapy while root causes are being corrected
Hormonal Optimization
- Bioidentical testosterone replacement when free testosterone is confirmed low, with monitoring of hematocrit, PSA, estradiol, and lipids
- Aromatase management when estradiol is elevated: reduce visceral adiposity (the aromatase source), zinc supplementation, and DIM (diindolylmethane) for estrogen metabolism support
- SHBG optimization: address the metabolic drivers (insulin resistance, thyroid dysfunction) that elevate SHBG and reduce free testosterone availability
- DHEA supplementation when adrenal androgens are depleted
What Most Doctors Miss
- ED is a cardiovascular warning, not just a sexual complaint: every man with ED should receive a comprehensive cardiovascular risk assessment. Treating ED without evaluating vascular risk is a missed prevention opportunity.
- Free testosterone, not total testosterone, determines hormonal adequacy: total testosterone can be "normal" while free testosterone is functionally depleted due to elevated SHBG. Free testosterone must be measured.
- Estradiol is not measured: elevated estradiol from aromatase overactivity suppresses testosterone signaling and contributes to ED. It is a common and treatable finding that standard ED evaluation does not assess.
- Insulin resistance is the most common undiagnosed driver: it simultaneously impairs endothelial function, promotes visceral adiposity, increases aromatase activity, and elevates estradiol. A single metabolic root cause producing multiple ED mechanisms.
When to Seek Medical Care
If you are experiencing erectile dysfunction at any age, a comprehensive evaluation of the vascular, hormonal, metabolic, and neurological mechanisms driving the dysfunction is warranted. ED in men under 50 is particularly significant as it identifies cardiovascular risk decades before events typically occur. Do not accept a PDE5 inhibitor prescription without a thorough investigation of why the ED developed.
Recommended Testing
Erectile dysfunction evaluation requires the comprehensive hormonal and cardiovascular panel that identifies the specific mechanisms producing the dysfunction and the cardiovascular risk it signals.
Hormonal
- Total Testosterone
- Free Testosterone
- SHBG
- Estradiol
- LH, FSH
- DHEA-S
- Prolactin
Metabolic and Cardiovascular
- Fasting Insulin / HOMA-IR
- HbA1c
- hs-CRP
- Lipid Panel + Triglyceride/HDL Ratio
- TSH, Free T3
Need cardiovascular and metabolic evaluation alongside hormone testing?
Explore All Testing Options →Frequently Asked Questions
What causes erectile dysfunction?
ED is caused by identifiable vascular, hormonal, metabolic, and neurological mechanisms. The most common are endothelial dysfunction, testosterone deficiency, insulin resistance, elevated estradiol, and autonomic impairment. Most men have multiple converging mechanisms.
Is erectile dysfunction a sign of heart disease?
Yes. ED is the earliest vascular warning sign, preceding cardiovascular events by 3 to 5 years. The same endothelial dysfunction producing ED is simultaneously affecting coronary arteries. ED should trigger a comprehensive cardiovascular risk evaluation.
Can low testosterone cause ED?
Yes. Testosterone is required for nitric oxide synthase expression, libido, and neurological arousal signaling. Free testosterone, not just total testosterone, must be measured. Elevated SHBG and estradiol can make total testosterone appear adequate while functional testosterone is depleted.
Should I just take Viagra?
PDE5 inhibitors are useful as bridge therapy while root causes are identified and treated, but they do not address the underlying vascular, hormonal, or metabolic dysfunction. Relying on them alone means the disease process continues to progress undetected.
What labs should I get for ED?
Total and free testosterone, SHBG, estradiol, LH, FSH, DHEA-S, fasting insulin, HOMA-IR, HbA1c, hs-CRP, lipid panel with triglyceride/HDL ratio, thyroid panel, and prolactin. These identify the specific mechanisms and the cardiovascular risk ED signals.
How The Lamkin Clinic Approaches Erectile Dysfunction
Clinical Perspective
When a man comes to me with erectile dysfunction, I do not reach for the prescription pad first. I reach for the lab order. ED is the body telling us that the vascular system is impaired, and the penile arteries are showing us first because they are the smallest. If I only prescribe sildenafil, I have helped him in the bedroom but I have done nothing about the cardiovascular disease that is building in his coronary arteries. When I measure his free testosterone, estradiol, fasting insulin, and hs-CRP, I can see exactly what is producing the ED and exactly what cardiovascular risk it represents. Then I treat both. That is the difference between a prescription and a medical evaluation.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
At The Lamkin Clinic, erectile dysfunction is evaluated as a systemic vascular and metabolic condition, not an isolated sexual complaint. Treatment targets the specific mechanisms producing the dysfunction: testosterone optimization when deficiency is confirmed, insulin sensitization for endothelial restoration, aromatase management for estradiol-driven suppression, cardiovascular risk reduction, and PDE5 inhibitor therapy as a bridge while root causes are being corrected. The goal is restored function through biological correction, not medication dependence.
Related Conditions
Endothelial DysfunctionThe vascular mechanism producing ED and predicting cardiovascular events
→Low TestosteroneTestosterone deficiency as a primary driver of ED and metabolic decline
→AndropauseAge-related hormonal decline producing progressive ED alongside metabolic changes
→Cardiovascular Disease RiskED as the earliest clinical warning of systemic vascular disease
→Insulin ResistanceThe metabolic root cause of endothelial dysfunction, aromatase elevation, and ED
→Metabolic SyndromeThe insulin-driven metabolic cluster producing converging ED mechanisms
→Related Symptoms
Chronic FatigueTestosterone and metabolic dysfunction producing energy decline alongside ED
→Brain FogTestosterone and metabolic impairment affecting cognition
→Depression BiologyLow testosterone as an underrecognized driver of male depression
→Obesity and Weight ManagementVisceral adiposity driving aromatase and estradiol-mediated ED
→Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Erectile dysfunction is the earliest vascular warning sign. It deserves a medical evaluation, not just a prescription.
The Lamkin Clinic evaluates ED as a systemic vascular and metabolic condition with comprehensive hormonal, metabolic, and cardiovascular assessment. Schedule a consultation.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.